These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23430361)

  • 21. Prognostic significance of ischemic electrocardiographic changes with regadenoson stress myocardial perfusion imaging.
    Doukky R; Nigatu A; Khan R; Anokwute C; Fughhi I; Ayoub A; Iskander F; Iskander M; Kola S; Sahyouni M; Karavolos K; Hota BN; Gomez J
    J Nucl Cardiol; 2020 Oct; 27(5):1521-1532. PubMed ID: 30132187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The EXERRT trial: "EXErcise to Regadenoson in Recovery Trial": A phase 3b, open-label, parallel group, randomized, multicenter study to assess regadenoson administration following an inadequate exercise stress test as compared to regadenoson without exercise for myocardial perfusion imaging using a SPECT protocol.
    Thomas GS; Cullom SJ; Kitt TM; Feaheny KM; Ananthasubramaniam K; Gropler RJ; Jain D; Thompson RC
    J Nucl Cardiol; 2017 Jun; 24(3):788-802. PubMed ID: 28224449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of regadenoson in patients with severe chronic obstructive pulmonary disease.
    Salgado-Garcia C; Jimenez-Heffernan A; Ramos-Font C; Lopez-Martin J; Sanchez-de-Mora E; Aroui T; Lopez-Aguilar R; Rivera-de-Los-Santos F; Ruiz-Frutos C
    Rev Esp Med Nucl Imagen Mol; 2016; 35(5):283-6. PubMed ID: 27160774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Considerations when measuring myocardial perfusion reserve by cardiovascular magnetic resonance using regadenoson.
    Bhave NM; Freed BH; Yodwut C; Kolanczyk D; Dill K; Lang RM; Mor-Avi V; Patel AR
    J Cardiovasc Magn Reson; 2012 Dec; 14(1):89. PubMed ID: 23272658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of global myocardial perfusion reserve using cardiovascular magnetic resonance of coronary sinus flow at 3 Tesla.
    Dandekar VK; Bauml MA; Ertel AW; Dickens C; Gonzalez RC; Farzaneh-Far A
    J Cardiovasc Magn Reson; 2014 Mar; 16(1):24. PubMed ID: 24674383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aminophylline and caffeine for reversal of adverse symptoms associated with regadenoson SPECT MPI.
    Doran JA; Sajjad W; Schneider MD; Gupta R; Mackin ML; Schwartz RG
    J Nucl Cardiol; 2017 Jun; 24(3):1062-1070. PubMed ID: 27025843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myocardial Stress Perfusion MRI: Experience in Pediatric and Young-Adult Patients Following Arterial Switch Operation Utilizing Regadenoson.
    Noel CV; Krishnamurthy R; Masand P; Moffett B; Schlingmann T; Cheong BY; Krishnamurthy R
    Pediatr Cardiol; 2018 Aug; 39(6):1249-1257. PubMed ID: 29748700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hemodynamic response, arrhythmic risk, and overall safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients.
    Husain Z; Palani G; Cabrera R; Karthikeyan AS; Dhanalakota S; Pathmanathan S; Jacobsen G; Ananthasubramaniam K
    Int J Cardiovasc Imaging; 2012 Oct; 28(7):1841-9. PubMed ID: 22200931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myocardial stress perfusion magnetic resonance: initial experience in a pediatric and young adult population using regadenoson.
    Noel CV; Krishnamurthy R; Moffett B; Krishnamurthy R
    Pediatr Radiol; 2017 Mar; 47(3):280-289. PubMed ID: 28035425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of a regimented aminophylline administration protocol on the burden of regadenoson-induced ischemia detected by SPECT myocardial perfusion imaging.
    Fughhi I; Campagnoli T; Ali A; Doukky R
    J Nucl Cardiol; 2017 Oct; 24(5):1571-1578. PubMed ID: 27233251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic and prognostic significance of ischemic electrocardiographic changes with regadenoson-stress myocardial perfusion imaging.
    Doukky R; Olusanya A; Vashistha R; Saini A; Fughhi I; Mansour K; Nigatu A; Confer K; Sims SA
    J Nucl Cardiol; 2015 Aug; 22(4):700-13. PubMed ID: 25907352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A(2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging.
    Thomas GS; Thompson RC; Miyamoto MI; Ip TK; Rice DL; Milikien D; Lieu HD; Mathur VS
    J Nucl Cardiol; 2009; 16(1):63-72. PubMed ID: 19152130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Attenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease--the ASSUAGE-CKD trial.
    Doukky R; Rangel MO; Dick R; Wassouf M; Alqaid A; Margeta B
    Int J Cardiovasc Imaging; 2013 Jun; 29(5):1029-37. PubMed ID: 23224354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: rationale and design of a prospective, randomized, multicenter study.
    Tejani FH; Thompson RC; Iskandrian AE; McNutt BE; Franks B
    J Nucl Cardiol; 2011 Feb; 18(1):73-81. PubMed ID: 21082298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of transient ischemic dilation with regadenoson myocardial perfusion imaging.
    Lester D; El-Hajj S; Farag AA; Bhambhvani P; Tauxe L; Heo J; Iskandrian AE; Hage FG
    J Nucl Cardiol; 2016 Oct; 23(5):1147-1155. PubMed ID: 26490267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gender-related differences in side-effects and hemodynamic response to regadenoson in patients undergoing SPECT myocardial perfusion imaging.
    Katsikis A; Kyrozi E; Manira V; Theodorakos A; Malamitsi J; Tsapaki V; Iakovou I; Voudris V; Kolovou G; Koutelou M
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2590-2600. PubMed ID: 31414207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease.
    Doukky R; Fughhi I; Campagnoli T; Wassouf M; Ali A
    J Nucl Cardiol; 2017 Feb; 24(1):112-118. PubMed ID: 26582040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An assessment of the safety, hemodynamic response, and diagnostic accuracy of commonly used vasodilator stressors in patients with severe aortic stenosis.
    Hussain N; Chaudhry W; Ahlberg AW; Amara RS; Elfar A; Parker MW; Savino JA; Titano R; Henzlova MJ; Duvall WL
    J Nucl Cardiol; 2017 Aug; 24(4):1200-1213. PubMed ID: 26979307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is regadenoson an appropriate stressor for MPI in patients with left bundle branch block or pacemakers?
    Thomas GS; Kinser CR; Kristy R; Xu J; Mahmarian JJ
    J Nucl Cardiol; 2013 Dec; 20(6):1076-85. PubMed ID: 24132816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review.
    Vij A; Golzar Y; Doukky R
    J Nucl Cardiol; 2018 Feb; 25(1):137-149. PubMed ID: 28653271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.